CLOs on the Move

GPO Plus

www.gpoplus.com

 
Headquartered in Las Vegas, Nevada, GPO Plus, Inc. (OTC: $GPOX) is a publicly traded global holding company of industry-specific Group Purchasing Organizations (GPO). The main holdings are HealthGPO, a Group Purchasing Organization for the Healthcare industry, and cbdGPO, a Group Purchasing Organization for the CBD and Hemp industry.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.gpoplus.com
  • 3571 East Sunset Road Suite 300
    Las Vegas, NV USA 89120
  • Phone: 702.840.1020

Executives

Name Title Contact Details

Similar Companies

JSS Medical Research

JSS Medical Research is a Westmount, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Samaritan Health Services

Samaritan Health Services is a non-profit network of hospitals,physician clinics and health services caring for the communities of the mid-Willamette Valley and central Oregon Coast. Our passion is providing world-class health care to our friends and neighbors. On the job and off, each of us brings the caring and personal commitment to enhance the health of the region we call home. We provide innovative medicine and world-class quality in a way that`s consistent with the values of the places we serve. That includes care and compassion for everyone, regardless of the ability to pay.

Colorado Health Care Association

Colorado Health Care Association is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SynCardia Systems

SynCardia Systems is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.